natgillin/translations-raw huggingface dataset:
The incidence of adverse reactions has been evaluated in six clinical trials involving approximately 4,000 adults and elderly receiving (Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics at least 7.5 µg HA, adjuvanted).
Učestalost nuspojava procijenjena je u šest kliničkih ispitivanja u kojima je bilo uključeno oko 4000 odraslih i starijih osoba koje su primile Prepandemijsko cjepivo protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics, najmanje 7,5 µg HA, adjuvantirano.
The incidence of adverse reactions in 384 subjects exposed to photodynamic therapy with Ameluz in pivotal clinical trials is listed below.
Incidencija nuspojava u 384 ispitanika podvrgnutih fotodinamskoj terapiji s lijekom Ameluz u glavnim kliničkim ispitivanjima navedena je u nastavku.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury (see section 4.4).
U liječenju centralne neuropatske boli uzrokovane ozljedom leđne moždine zabilježena je povećana incidencija nuspojava općenito te nuspojava središnjeg živčanog sustava, a osobito somnolencije (vidjeti dio 4.4).
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury (see section 4.4).
Učestalost nuspojava općenito, nuspojava povezanih sa središnjim živčanim sustavom i osobito pospanosti bila je povećana pri liječenju središnje neuropatske boli uzrokovane ozljedama leđne moždine (vidjeti dio 4.4).
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
U liječenju centralne neuropatske boli uzrokovane ozljedom leđne moždine zabilježena je povećana incidencija nuspojava općenito te nuspojava središnjeg živčanog sustava, a osobito somnolencije.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Učestalost nuspojava općenito, nuspojava povezanih sa središnjim živčanim sustavom i osobito pospanosti bila je povećana pri liječenju središnje neuropatske boli uzrokovane ozljedama leđne moždine.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Zabilježena je povećana incidencija nuspojava općenito te nuspojava središnjeg živčanog sustava, a osobito somnolencije, u liječenju centralne neuropatske boli uzrokovane ozljedom leđne moždine.
The incidence of adverse reactions listed above have the potential to occur with a higher frequency in patients who have a poor performance status (see section 4.4).
Incidencija navedenih nuspojava potencijalno je veća u bolesnika slabog općeg stanja (vidjeti dio 4.4).
The incidence of adverse reactions was evaluated in four clinical trials with different influenza strains and formulations (H5N3, H9N2 and H5N1); 3696 adults and elderly subjects were exposed.
Učestalost nuspojava procijenjena je u četiri klinička ispitivanja s različitim sojevima gripe i formulacijama (H5N3, H9N2 i H5N1); cijepljeno je 3696 odraslih i starijih ispitanika.
The incidence of AEs, including Grade  3 AEs and SAEs, was similar between the two treatment arms.
Incidencija štetnih događaja, uključujući štetne događaje stupnja  3 i ozbiljne štetne događaje, bila je slična u obje liječene skupine.
The incidence of all cause mortality at Day 30 was also significantly reduced from 8.9% for the control group to 7.8% in the fondaparinux group (hazard ratio 0.87, 95% CI, 0.77;0.98, p = 0.02).
Incidencija mortaliteta svih uzroka tridesetog dana bila je također značajno smanjena s 8,9% u kontrolnoj skupini na 7,8% u skupini liječenoj fondaparinuksom (omjer rizika 0,87; 95% CI, 0,77; 0,98, p = 0,02).
The incidence of all grade peripheral neuropathy with bortezomib administered intravenously was lower in the historical studies with bortezomib administered intravenously than in study MMY-3021.
Incidencija perifrene neuropatije svih stupnjeva uz intravensku primjenu bortezomiba bila je niža u prethodnim ispitivanjima s bortezomibom primijenjenim intravenski, nego u ispitivanju MMY-3021.
The incidence of all grade peripheral neuropathy with bortezomib administered intravenously was lower in the historical studies with bortezomib administered intravenously than in study MMY-3021.
Incidencija perifrene neuropatije svih stupnjeva uz intravensku primjenu bortezomiba bila je niža u prethodnim ispitivanjima s bortezomibom primjenjenim intravenski, nego u ispitivanju MMY-3021.
The incidence of angioedema in patients not taking concomitant ACE inhibitors was the same in both groups.
Učestalost angioedema u bolesnika koji nisu uzimali ACE inhibitore bila je ista u obje skupine.
The incidence of binding antibodies (excluding predose positive patients) was 1% as detected by the acid-dissociation ELISA and < 1% as detected by the Biacore assay;
Incidencija vežućih protutijela (isključujući bolesnike pozitivne prije primjene prve doze) bila je 1%, detektiranih kiselinsko-disocirajućim testom ELISA i < 1% detektirano testom Biacore;
The incidence of biopsy confirmed acute rejection was higher (p=0.020*) for patients in the sirolimus group (11, 8.4%) compared to the tacrolimus group (2, 1.6%) through 2 years; most rejections were mild in severity (8 of 9 [89%] T-cell BCAR, 2 of 4 [50%] antibody mediated BCAR) in the sirolimus group.
Incidencija biopsije potvrdila je da je akutno odbacivanje bilo više (p = 0,020) u bolesnika u skupini koja je primala sirolimus (11, 8,4%) u usporedbi sa skupinom liječenom takrolimusom (2, 1,6%) kroz dvije godine; većina odbacivanja bila je blagog intenziteta (8 od 9 [89%] BCAR posredovan T-stanicama, 2 od 4 [50%] protutijelima posredovan BCAR) u skupini sa sirolimusom.
The incidence of blood and lymphatic systems disorders adverse reactions observed across all cycles in the moderate and severe renal impairment patients were 28.6% and 44.4%, respectively.
Incidencija nuspojava poremećaja krvi i limfnog sustava uočenih kroz sve cikluse u bolesnika sa umjerenim ili teškim oštećenjem bubrega iznosile su 28,6 % i 44,4
The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with erythropoietin for 3 years compared to a matched control group of dialysis patients who had not been treated with erythropoietin).
U ispitivanjima provedenima na bolesnicima na hemodijalizi incidencija fibroze koštane srži nije povećana kod onih koji su bili liječeni eritropoetinom tijekom 3 godine u odnosu na usklađenu kontrolnu skupinu bolesnika na dijalizi koji nisu bili liječeni s eritropoetinom).
The incidence of both ACUITY-scale and TIMI-scale bleeding events to day 30 for the per protocol population are presented in Table 7.
Incidencija krvarenja, prema ljestvicama ACTUITY i TIMI za 30 dana za populaciju prema planu ispitivanja prikazana je u tablici 7.
The incidence of both ACUITY-scale and TIMI-scale bleeding events up to day 30 for the intent-to- treat population is presented in Table 6.
Incidencija krvarenja, prema ljestvicama ACTUITY i TIMI, do 30 dana u populaciji s namjerom liječenja (ITT) prikazana je u tablici 6.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8)
Incidencija klinički značajnog krvarenja bila je slična onoj zamijećenoj pri istodobnoj primjeni trombolitika i heparina s ASK (vidjeti dio 4.8).
The incidence of confirmed hypoglycaemic events was somewhat higher in the saxagliptin group (9.4%) versus placebo group (4.7%) although the number of subjects with any hypoglycaemic event did not differ between the treatment groups.
Incidencija potvrđenih hipoglikemijskih epizoda bila je nešto veća u skupini koja je primala saksagliptin (9,4%) nego u placebo skupini (4,7%), premda nije bilo razlike u broju ispitanika s bilo kojim hipoglikemijskim događajem između te dvije terapijskih skupina.
The incidence of DAGT seroconversion in patients receiving ceftaroline fosamil was 10.7% in the four pooled pivotal studies with administration every 12 hours (600 mg administered over 60 minutes every 12 hours) and 32.3% in a study in patients receiving ceftaroline fosamil every 8 hours (600 mg administered over 120 minutes every 8 hours), (see section 4.8).
Incidencija serokonverzije DAGT-a u bolesnika koji su primali ceftarolinfosamil iznosila je 10,7% u objedinjenim podacima iz četiri pivotalne studije uz primjenu svakih 12 sati (600 mg primijenjeno tijekom 60 minuta, svakih 12 sati) te 32,3% u studiji na bolesnicima koji su primali ceftarolinfosamil svakih 8 sati (600 mg primijenjeno tijekom 120 minuta, svakih 8 sati).
The incidence of DAGT seroconversion in patients receiving ceftolozane/tazobactam was 0.2% in the clinical trials.
U kliničkim je ispitivanjima incidencija serokonverzije dokazane DAGT-om u bolesnika koji su primali ceftolozan/tazobaktam bila 0,2%.
The incidence of delayed hip fracture healing was comparable between Aclasta (34 [3.2%]) and placebo (29 [2.7%]).
Incidencija odgođenog zarastanja prijeloma kuka bila je usporediva za Aclastu (34 [3,2%]) i placebo (29 [2,7%]).
The incidence of delayed hip fracture healing was comparable between zoledronic acid (34 [3.2%]) and placebo (29 [2.7%]).
Incidencija odgođenog zarastanja prijeloma kuka bila je usporediva za zoledronatnu kiselinu(34 [3,2%]) i placebo (29 [2,7%]).
The incidence of diarrhoea, dizziness, asthenia, weight decrease, and dehydration was increased by ≥5% in older people compared to younger patients.
Incidencija proljeva, omaglice, astenije, smanjenja tjelesne težine i dehidracije bila je ≥ 5% veća u starijih nego u mlađih bolesnika.
The incidence of discontinuation due to medicine related hepatic disorders was 5% in Zinbryta-treated patients and 4% in interferon beta-1a (intramuscular).
Incidencija prekida liječenja zbog jetrenih poremećaja povezanih s lijekom iznosila je 5% kod bolesnika liječenih Zinbrytom i 4% kod bolesnika liječenih interferonom beta-1a (intramuskularno).
The incidence of diverticulitis was comparable between treatment groups in postmenopausal women or men with osteoporosis and in women undergoing aromatase inhibitor therapy for nonmetastatic breast cancer.
Incidencija divertikulitisa je bila usporediva u terapijskim skupinama žena u postmenopauzi ili muškaraca s osteoporozom i žena koje primaju terapiju inhibitorima aromataze zbog nemetastazirajućeg raka dojke.
The incidence of drug-related skin disorder, skin ulcer, pain and rash appeared to be greater in patients applying Panretin gel four times daily than in those applying it less frequently.
Incidencija kožnog poremećaja povezanog s lijekom, kožnog ulkusa, bola i osipa čini se da je veća u bolesnika koji su primjenjivali Panretin četiri puta na dan nego u onih koji su ga primjenjivali manje učestalo.
The incidence of each thromboembolic component of the primary outcome was also significantly reduced in fondaparinux patients as follows: symptomatic PE [0 (0%) vs 5 (0.3%) (p=0.031)], symptomatic DVT [3 (0.2%) vs 18 (1.2%); relative risk reduction 83.4% (p<0.001)], symptomatic superficial-vein thrombosis extension [4 (0.3%) vs 51 (3.4%); relative risk reduction 92.2% (p<0.001)], symptomatic superficial-vein thrombosis reoccurrence [5 (0.3%) vs 24 (1.6%); relative risk reduction 79.2% (p<0.001)].
Incidencija svake tromboembolijske komponente primarnog ishoda je također značajno smanjena u fondaparinuks skupini bolesnika kako slijedi: simptomatska PE [0 (0%) naspram 5 (0,3%) (p=0,031)], simptomatska DVT [3 (0,2%) naspram 18 (1,2%); relativna redukcija rizika od 83,4% (p<0,001)], simptomatsko proširenje (ekstenzija) tromboze površinske vene [4 (0,3%) vs 51 (3,4%); relativna redukcija rizika od 92,2% (p<0,001)], recidiv simptomatske tromboze površinske vene [5 (0,3%) vs 24 (1,6%); relativna redukcija rizika od 79,2% (p<0,001)].
The incidence of efficacy failure at 12 months (defined as death, graft loss, biopsy-confirmed acute rejection, or lost to follow-up) was 14.0% in the Advagraf group (N=214), 15.1% in the Prograf group (N=212) and 17.0% in the ciclosporin group (N=212).
Incidencija neuspješne djelotvornosti nakon 12 mjeseci (definirane kao smrt, gubitak presatka, biopsijom potvrđeno akutno odbacivanje ili bolesnici odustali/isključeni tijekom praćenja) iznosila je 14,0% u skupini koja je primala Advagraf (N=214), 15,1% u skupini koja je primala Prograf (N=212) i 17,0% u skupini koja je primala ciklosporin (N=212).
The incidence of erythema multiforme or Stevens- Johnson syndrome was approximately 0.1%.
Incidencija multiformnog eritema ili Stevens-Johnsonovog sindroma bila je približno 0,1%.
The incidence of fatal VTEs was similar between arms (0.2%).
Incidencija VT događaja sa smrtnim ishodom bila je slična u obje skupine (0,2%).
The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel alone).
Incidencija febrilne neutropenije/neutropenijske sepse također je bila povećana u bolesnika koji su liječeni Herceptinom i docetakselom (23% u odnosu na 17% bolesnika koji su liječeni samo docetakselom u monoterapiji).
The incidence of flu-like symptoms (e.g. influenza-like illness, chills, hyperpyrexia, musculoskeletal pain, myalgia, pain, pyrexia) was highest at the initiation of treatment and generally decreased over the first 6 months.
Incidencija simptoma nalik gripi (npr. bolest nalik gripi, zimica, hiperpireksija, mišićno-koštana bol, mijalgija, bol, pireksija) bila je najviša na početku liječenja, a općenito se smanjila tijekom prvih 6 mjeseci.
The incidence of FN varied according to age (from 14.3 % to 71.4 %), with the highest frequency in the oldest age group.
Incidencija febrilne neutropenije varirala je ovisno o dobi (od 14,3 % do 71,4 %) s najvećom učestalošću u najstarijoj dobnoj skupini.
The incidence of fractures was 8 for zoledronic acid- treated patients versus 7 for risedronate-treated patients (p=0.8055).
Incidencija prijeloma bila je 8 bolesnika liječenih zoledronatnom kiselinom u odnosu na 7 bolesnika liječenih risedronatom (p=0,8055).
The incidence of Grade 3 hand-foot skin reaction in Asians was 28.4% (CRC) and 23.5% (GIST) (see sections 4.2 and 4.4).
Incidencija kožne reakcije na šakama i stopalima 3.stupnja u bolesnika azijskog podrijetla bila je 28,4% (KRK) i 23,5% (GIST) (vidjeti dijelove 4.2 i 4.4).
The incidence of Grade 3 hand-foot skin reaction was 16.6% (CRC) and 22.0% (GIST).
Incidencija kožne reakcije na šakama i stopalima 3. stupnja iznosila je 16,6% (KRK) i 22,0% (GIST).
The incidence of Grade 3 hypertension was 7.6% (CRC) and 27.3% (GIST).
Incidencija hipertenzije 3. stupnja iznosila je 7,6% (KRK) i 27,3% (GIST).
The incidence of grade ≥3 anaemia, increased AST, ALT, and bilirubin based on laboratory abnormalities were 10.5%, 0.7%, 0.9%, and 0.6%, respectively.
Na temelju odstupanja laboratorijskih vrijednosti, incidencija anemije stupnja ≥ 3 iznosila je 10,5%, incidencija povišenih vrijednosti AST-a 0,7%, incidencija povišenih vrijednosti ALT-a 0,9%, a incidencija povišenih vrijednosti bilirubina 0,6%.
The incidence of haemorrhagic events (11% G+B, 10% B) and Grade 3-5 haemorrhagic events (5% G+B, 3%B) was similar in both treatment arms with no fatal events reported.
Incidencija događaja krvarenja (11% uz G+B, 10% uz B) i događaja krvarenja 3. – 5. stupnja (5% uz G+B, 3% uz B) bila je slična u obje liječene skupine, a nije prijavljen nijedan smrtni slučaj.
The incidence of herpes zoster among patients in the VcR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).
Incidencija herpes zostera među bolesnicima u VcR-CAP skupini bila je 10,7% za bolesnike kojima nije bila primijenjena antivirusna profilaksa u uspredbi s 3,6% za bolesnike kojima je primijenjena antivirusna profilaksa (vidjeti dio 4.4).
The incidence of HIV seroconversion is shown in Table 9.
Incidencija serokonverzije HIV-a prikazana je u Tablici 9.
The incidence of hypersensitivity reactions was 1.1% in both Onglyza-treated patients and placebo- treated patients.
Incidencija reakcija preosjetljivosti iznosila je 1,1% i u bolesnika liječenih lijekom Onglyza i u onih koji su primali placebo.
The incidence of hypersensitivity reactions was 1.1% in both saxagliptin-treated patients and placebo-treated patients.
Incidencija reakcija preosjetljivosti iznosila je 1,1% i u bolesnika liječenih saksagliptinom i u onih koji su primali placebo.
The incidence of hypoglycaemia was 25.2 % in patients treated with sitagliptin and insulin (with or without metformin) and 36.8 % in patients treated with placebo and insulin (with or without metformin).
Incidencija hipoglikemije bila je 25,2% u bolesnika liječenih sitagliptinom i inzulinom (s metforminom ili bez njega), a 36,8% u bolesnika koji su liječeni placebom i inzulinom (s metforminom ili bez njega).
The incidence of hypoglycaemia was increased when prolonged-release exenatide was used in combination with a sulphonylurea (24.0 % versus 5.4 %) (see section 4.4).
Incidencija hipoglikemije je bila povećana kada se eksenatid s produljenim oslobađanjem primjenjivao u kombinaciji sa sulfonilurejom (24,0% naspram 5,4%) (vidjeti dio 4.4).
The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs.
Incidencija hipoglikemije bila je niža u skupini liječenoj vildagliptinom nego u skupini liječenoj placebom (22,9% u odnosu na 29,6%).
The incidence of ILD was 6.2% in patients of Japanese ethnicity, 1.2% in patients of Asian ethnicity and 2.4% in non-Asian patients. (See Section 4.8).
Incidencija IBP-a je bila 6,2% u bolesnika japanskog porijekla, 1,2% u bolesnika azijskog porijekla i 2,4% u bolesnika ne-azijskog porijekla. (Vidjeti dio 4.8).
The incidence of infection was 38% in the Gazyvaro plus chlorambucil arm and 37% in the rituximab plus chlorambucil arm (with Grade 3-5 events reported in 12% and 14%, respectively and fatal events reported in < 1% in both treatment arms).
Incidencija infekcije iznosila je 38% u skupini liječenoj lijekom Gazyvaro i klorambucilom te 37% u skupini liječenoj rituksimabom i klorambucilom (događaji 3.-5. stupnja prijavljeni su u 12% bolesnika liječenih lijekom Gazyvaro i klorambucilom i u 14% bolesnika koji su primali rituksimab i klorambucil, a incidencija smrtnih slučajeva u obje je liječene skupine bila manja od 1%).
The incidence of infection was 65% in the G+B arm and 56% in the B arm (with Grade 3-5 events reported in 18% and 17%, respectively, and fatal events reported in 5 patients (3%) in the G+B and 7 patients (4%) in the B arm).
Incidencija infekcije iznosila je 65% u skupini koja je primala G+B te 56% u onoj koja je primala samo B (događaji 3. – 5. stupnja prijavljeni su u 18% odnosno 17% bolesnika, a smrtni slučajevi u 5 bolesnika (3%) liječenih kombinacijom G+B te u 7 bolesnika (4%) koji su primali samo B).
The incidence of infections leading to dose interruptions was also numerically higher in patients weighing <30 kg treated with 10 mg/kg tocilizumab (21.4%) compared to patients weighing ≥30 kg, treated with 8 mg/kg tocilizumab (7.6%).
Incidencija infekcija koje su dovele do prekida liječenja također je bila brojčano viša kod bolesnika tjelesne težine < 30 kg liječenih tocilizumabom u dozi od 10 mg/kg (21,4%) nego kod bolesnika tjelesne težine ≥ 30 kg liječenih tocilizumabom u dozi od 8 mg/kg (7,6%).
The incidence of infusion-related symptoms decreased substantially with subsequent infusions and is <1% of patients by the eighth cycle of MabThera-containing treatment.
Incidencija pojave simptoma povezanih s infuzijom znatno se smanjila u narednim infuzijama te je do osmog ciklusa terapije koja je sadržavala lijek MabThera iznosila < 1%.
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1 % after eight doses of MabThera.
Incidencija simptoma povezanih s infuzijom znatno se smanjuje u sljedećim infuzijama te nakon osam doza lijeka MabThera iznosi manje od 1%.
The incidence of injection site reactions may be reduced by the use of an auto-injector.
Incidencija reakcija na mjestu primjene može se smanjiti korištenjem autoinjektora.
The incidence of injection site reactions may be reduced by the use of an autoinjector.
Incidencija reakcija na mjestu injiciranja može se smanjiti primjenom autoinjektora.
The incidence of IRRs in subsequent infusions was comparable in both arms and decreased with each cycle.
Incidencija reakcija na infuziju kod sljedećih infuzija bila je usporediva u obje skupine te se smanjivala sa svakim ciklusom.
The incidence of IRRs was 65% with the infusion of the first 1,000 mg of Gazyvaro (20% of patients experiencing a Grade 3-5 IRR, with no fatal events reported).
Incidencija reakcija na infuziju iznosila je 65% tijekom infuzije prvih 1000 mg lijeka Gazyvaro (20% bolesnika imalo je reakciju na infuziju 3.-5. stupnja, ali nije prijavljen niti jedan smrtni slučaj).
The incidence of IRRs was higher in the Gazyvaro plus chlorambucil arm compared to the rituximab plus chlorambucil arm.
Incidencija reakcija na infuziju bila je veća u skupini liječenoj lijekom Gazyvaro i klorambucilom nego u skupini liječenoj rituksimabom i klorambucilom.
The incidence of IRRs with subsequent infusions was 3% with the second 1,000 mg dose and 1% thereafter.
Incidencija reakcija na infuziju pri sljedećim infuzijama iznosila je 3% tijekom druge doze od 1000 mg te 1% nakon toga.
The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.
Incidencija značajnog gastrointestinalnog krvarenja prema ISTH (uključujući krvarenje u gornjem odnosno donjem dijelu GI trakta i rektalno krvarenje) iznosila je 0,76% na godinu za apiksaban i
The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.
Incidencija značajnog gastrointestinalnog krvarenja prema ISTH (uključujući krvarenje u gornjem odnosno donjem dijelu GI trakta i rektalno krvarenje) iznosila je 0,76% na godinu za apiksaban i 0,86% na godinu za varfarin.
The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.
Incidencija značajnog intraokularnog krvarenja prema ISTH kod primjene apiksabana iznosila je 0,18% na godinu.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any conditions associated with hypoxia.
Incidencija laktacidoze se može i mora smanjiti procjenom drugih povezanih faktora rizika poput loše kontrolirane šećerne bolesti, ketoze, produljenog gladovanja, pretjeranog unosa alkohola, oštećenja jetre i bilo kojih stanja povezanih s hipoksijom.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Incdencija laktacidoze može se i mora smanjiti tako da se u obzir uzmu i ostali čimbenici rizika poput loše kontrole dijabetesa, ketoze, produženog gladovanja, prekomjerne konzumacije alkohola, insuficijencije jetre i svih stanja povezanih s hipoksijom.